Although sigma receptors were discovered in 1982, the biochemical and physiological roles of sigma receptors have just begun to unveil. Sigma receptors are non-opioid, non-phencyclidine receptors that contain two subtypes: sigma-1 and sigma-2 receptors. The sigma-1 receptor has been cloned and its sequence does not resemble that of any mammalian protein. Sigma-2 receptors have not been cloned. The focus of this review will be on sigma-1 receptors. Sigma-1 receptors contain 223 amino acids and reside primarily at the endoplasmic reticulum. Sigma-1 receptors exist mainly in the central nervous system, but also in the periphery. Sigma-1 receptor ligands include cocaine, (+)-benzomorphans like (+)-pentazocine and (+)N-allyl-normetazocine (or (+)-SKF-10047), and endogenous neurosteroids like progesterone and pregnenolone sulfate. Many pharmacological and physiological actions have been attributed to sigma-1 receptors. These include the regulation of IP3 receptors and calcium signaling at the endoplasmic reticulum, mobilization of cytoskeletal adaptor proteins, modulation of nerve growth factor-induced neurite sprouting, modulation of neurotransmitter release and neuronal firing, modulation of potassium channels as a regulatory subunit, alteration of psychostimulant-induced gene expression, and blockade of spreading depression. Behaviorally, sigma-1 receptors are involved in learning and memory, psychostimulant-induced sensitization, cocaine-induced conditioned place preference, and pain perception. Notably, in almost all the aforementioned biochemical and behavioral tests, sigma-1 agonists, while having no effects by themselves, caused the amplification of signal transductions incurred upon the stimulation of the glutamatergic, dopaminergic, IP3-related metabotropic, or nerve growth factor-related systems. Thus, it is hypothesized that sigma-1 receptors, at least in part, are intracellular amplifiers creating a supersensitized state for signal transduction in the biological system.
HISTORY AND INTRODUCTIONOriginally intending to identify a subtype of opioid receptors, the sigma/opioid receptors as proposed by Martin et al.. [1], Su [2] used the tritiated prototypic sigma/opioid receptor ligand SKF-10047 (N-allyl-normetazocine) in binding assays and identified a protein that has a nanomolar affinity for SKF-10047. Surprisingly though, the protein had no affinity for the opioid antagonist naloxone. This raised a possibility that the protein identified by Su [2] may not be the sigma/opioid receptor proposed by Martin et al..[1] but may represent a new receptor at which SKF-10047 has an affinity. The protein identified by Su [2] was later termed "sigma receptor", with the word "opioid" dropped to differentiate it from the sigma/opioid receptor and the word "sigma" retained for it being identified with the labeled ligand SKF-10047. So far, the sigma/opioid receptor proposed by Martin et al.. has not been clearly identified.The sigma receptor has several peculiarities in its ligand binding profile and its distri...